ArticlePharmacological reports : PR2026
Elevated hypoxia-inducible factor-1α in pediatric patients with patent ductus arteriosus: a pilot study.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildren with complex cyanotic congenital heart disease (CHD) and with pulmonary hypertension (PH) commonly experience hypoxia. Hypoxia-inducible factor-1α (HIF-1α) is a key regulator of cellular responses to low oxygen, and its levels are elevated in these conditions. However, HIF-1α concentrations in non-cyanotic CHD, such as patent ductus arteriosus (PDA), remain largely unknown. This study aimed to evaluate circulating serum HIF-1α levels in patients with PDA and compare them with those in healthy children and in patients with complex CHD after Fontan palliation.
methodsEighty children were assigned to three groups: PDA group (n = 34), Fontan group (n = 23), and healthy controls (n = 23). Complete blood counts, serum HIF-1α levels, and baseline clinical characteristics were collected. Multiple regression analysis was performed to identify predictors of HIF-1α variability. Receiver operating characteristic (ROC) curves were analyzed to evaluate the ability of selected variables to predict increased HIF-1α levels.
resultsPatients with PDA exhibited the highest median [IQR] HIF-1α levels (0.62 [0.41-1.18] ng/mL), compared to patients in the Fontan group (0.52 [0.34-0.73] ng/mL), and healthy controls (0.48 [0.33-0.63] ng/mL) (p = 0.03). In the combined CHD cohort, hemoglobin, age, and red blood cell count formed the best predictive model, explaining 53.9% of HIF-1α variance (p < 0.01). Hematocrit < 36.6% and hemoglobin < 12.9 g/dL showed the best diagnostic accuracy for identifying HIF-1α > 1.1 ng/mL.
conclusionsChildren with PDA, even without PH, exhibit elevated circulating HIF-1α. Further research is needed to clarify the clinical relevance of HIF-1α in non-cyanotic CHD.
Indexed as
Identifiers
42527758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.